Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia.
For more information, please visit www.thereliefstudy.com or www.clinicaltrials.gov (NCT04172831).

Improving the Landscape

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) (Tonix) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics. We focus on developing small molecules and biologics to treat psychiatric, pain and addiction conditions.

Our mission is to improve the lives of patients by identifying, researching and developing promising therapies which have the potential to address needs not currently fulfilled by existing products.

Learn more

Latest News

Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering

• February 11, 2020 • 4:01 PM EST

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company,…

Read more

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate, TNX-102 SL, is being developed for the treatment of fibromyalgia.

View Pipeline

About Tonix Pharmaceuticals

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat pain, addiction and psychiatric conditions. Tonix’s lead product candidate, TNX-102 SL*, is in development for fibromyalgia, agitation in Alzheimer’s disease and alcohol use disorder (AUD). TNX-102 SL is in Phase 3 development as a bedtime treatment for fibromyalgia. The Company has started enrollment in the Phase 3 RELIEF trial in fibromyalgia and expects interim data in the third quarter of 2020. The agitation in Alzheimer’s disease program is Phase 2 ready and the development for AUD is in the pre-Investigational New Drug (IND) application stage. TNX-601 CR (tianeptine oxalate controlled-release tablets) is in development as a daytime treatment for PTSD, as well as for depression. The first efficacy study will be performed outside the U.S. and it is expected to be IND-ready in 2020. TNX-1600 (a triple reuptake inhibitor) is a third product candidate being developed for PTSD, as a daytime treatment. Tonix‘s programs for treating addiction conditions also include TNX-1300** (double-mutant cocaine esterase), which is in Phase 2 development for the treatment of cocaine intoxication. Tonix’s preclinical pipeline includes TNX-1500 (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection and autoimmune conditions, and TNX-1700 (rTFF2), a biologic being developed to treat gastric and pancreatic cancers. Finally, TNX-801 (live virus vaccine for percutaneous [scarification] administration) to potentially prevent smallpox and TNX-701 (undisclosed small molecule) to prevent radiation effects are being advanced as medical countermeasures to improve biodefense.

*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.

**TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) is an investigational new biologic and has not been approved for any indication.

Learn more about tonix